In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Pasireotide | Synthetic analog Octreotide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 517 | 816 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 154 (154 in people) | 118 (116 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 76 · 4 active7 more mention it but do not test it | 256 · 30 active63 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Signifor says: “Adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pasireotide | Octreotide |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormones | 35296 | 14513411 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Sandostatin says: “Reduction of GH and IGF-1 in acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine”
8787 |
69672 |
| Tumor growthEndocrine and hormones | 5643211 | 654916 |
|---|
| Glycemic controlMetabolic and weight | 56506 | 4747 |
|---|
| Gastrointestinal protectionGastrointestinal | 11 | 91901 |
|---|
| PharmacokineticsPharmacology | 4848 | 21192 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 3131 | 3434 |
|---|
| Receptor activity and mechanismPharmacology | 6714251 | 35269 |
|---|
| MortalityWhole body | 761 | 4040 |
|---|
| Blood pressureCardiovascular | 33 | 22202 |
|---|
| Kidney functionKidney and urinary | 422 | 25169 |
|---|
| Quality of lifeWhole body | 1515 | 33 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Pasireotide | Octreotide |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in % | 31.3% Biochemical control rate Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn = 3582014 | 19.2% Biochemical control rate Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn = 3582014 |
| Tumor growthEndocrine and hormonesCompared as: value in the arm that got the peptide, in months | 11.8 months Median progression-free survival Dose studied: 60 mg every 28 daysn not reported2015 | |
| Adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 57.3% Hyperglycemia-related adverse event rate Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn not reported2014 |
31.3%
Biochemical control rate
Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn = 3582014
19.2%
Biochemical control rate
Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn = 3582014
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pasireotide | Octreotide |
|---|---|---|
| MortalityWhole bodyCompared as: difference from placebo, in p | No comparable result 1 randomized-trial result measure it in another way or another unit. | 0.34 P P value Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009 |
14.3 months
Median time to tumor progression
Placebo group: 6 months
Dose studied: 30 mg monthlyn = 852009
21.7% Hyperglycemia-related adverse event rate Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn not reported2014 |
11.8 months
Median progression-free survival
Dose studied: 60 mg every 28 daysn not reported2015
14.3 months
Median time to tumor progression
Placebo group: 6 months
Dose studied: 30 mg monthlyn = 852009
57.3%
Hyperglycemia-related adverse event rate
Dose studied: 40 mg/28 days, with optional titration to 60 mg at months 3 and 712 monthsn not reported2014
21.7%
Hyperglycemia-related adverse event rate
Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn not reported2014
| Quality of lifeCancerCompared as: difference from placebo, in p | No comparable result 2 randomized-trial results measure it in another way or another unit. | 0.09 P P value Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009 |
|---|
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in ml/m | −99 ml/m Annualized absolute change in height-adjusted total liver volume · pasireotide LAR group; ±189 Placebo group; ±117: 136 ml/m 1 yearn = 412020 | No comparable result 6 randomized-trial results measure it in another way or another unit. |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in l/h | No comparable result 2 randomized-trial results measure it in another way or another unit. | 15.8 L/h Apparent clearance · octreotide 100 microg Dose studied: 100 microgsingle dosen = 122005 |
|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in mg/dl h | No comparable result 4 randomized-trial results measure it in another way or another unit. | 39 to 40 mg/dl h Difference in mean change of blood glucose AUC(0-180 min) vs placebo, OGTT 6 monthsn not reported2006 |
|---|
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in ml/m | −12 ml/m Change in total kidney volume · pasireotide LAR group; ±34 Placebo group; ±21: 21 ml/m 1 yearn not reported2020 | No comparable result 8 randomized-trial results measure it in another way or another unit. |
|---|
| Gastrointestinal protectionGastrointestinalCompared as: difference from placebo, in p | No randomized trial result 1 result from other study designs. | 0.046 P P value Dose studied: 0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusionIntravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedn = 8322007 |
|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | No randomized trial result 3 results from other study designs. | 1.6 kg Weight change, mean · octreotide group; SEM 0.6 Placebo group; SEM 1.7: 9.1 kg Dose studied: 5-15 microg/kg per day6 monthsn = 182003 |
|---|
| Gastrointestinal motilityGastrointestinalCompared as: value in the arm that got the peptide, in min | 83 min Solid gastric emptying half-time · pasireotide 300 μg t.i.d.; ± 23 Placebo; ± 9: 43 min Dose studied: 300 μg t.i.d.2 weeksn not reported2014 | No randomized trial result 2 results from other study designs. |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
0.34 P
P value
Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009
No comparable result
2 randomized-trial results measure it in another way or another unit.
0.09 P
P value
Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009
−99 ml/m
Annualized absolute change in height-adjusted total liver volume · pasireotide LAR group; ±189
Placebo group; ±117: 136 ml/m
1 yearn = 412020
No comparable result
6 randomized-trial results measure it in another way or another unit.
No comparable result
2 randomized-trial results measure it in another way or another unit.
15.8 L/h
Apparent clearance · octreotide 100 microg
Dose studied: 100 microgsingle dosen = 122005
No comparable result
4 randomized-trial results measure it in another way or another unit.
39 to 40 mg/dl h
Difference in mean change of blood glucose AUC(0-180 min) vs placebo, OGTT
6 monthsn not reported2006
−12 ml/m
Change in total kidney volume · pasireotide LAR group; ±34
Placebo group; ±21: 21 ml/m
1 yearn not reported2020
No comparable result
8 randomized-trial results measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
0.046 P
P value
Dose studied: 0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusionIntravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedn = 8322007
No randomized trial result
3 results from other study designs.
1.6 kg
Weight change, mean · octreotide group; SEM 0.6
Placebo group; SEM 1.7: 9.1 kg
Dose studied: 5-15 microg/kg per day6 monthsn = 182003
83 min
Solid gastric emptying half-time · pasireotide 300 μg t.i.d.; ± 23
Placebo; ± 9: 43 min
Dose studied: 300 μg t.i.d.2 weeksn not reported2014
No randomized trial result
2 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 76 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Memorial Sloan Kettering Cancer Center439 participantsOct 2009 to Sept 2014
Pancreatic Cancer
Novartis Pharmaceuticals358 participants11 Feb 2008 to 11 Mar 2016
Acromegaly
RECORDATI GROUP337 participants10 Jun 2013 to 25 Jul 2023
Cushing's Disease · Acromegaly · Neuroendocrine Tumors · Pituitary Tumors · Ectopic ACTH Secreting (EAS) Tumors · Dumping Syndrome · Prostate Cancer · Melanoma Negative for bRAF · Melanoma Negative for nRAS
7 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 256 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Korea University1,034 participantsSept 2006 to May 2010
Variceal Bleeding, Cirrhosis
Novartis Pharmaceuticals429 participantsDec 2006 to Jun 2013
Carcinoid Tumor · Malignant Carcinoid Syndrome
National Cancer Institute (NCI)427 participants1 Dec 2007 to est. 31 Jan 2027
Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1 · Neuroendocrine Neoplasm · Neuroendocrine Tumor · Neuroendocrine Tumor G2
63 more mention it but do not test it. They only measure it or name it in their text.